Please assess the completion status of the following clinical trial:

Trial Title: Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weigh between 35-135 kilograms~* Low or int-1 risk MDS~* Ferritin \>1000 micrograms/liter at screening~* History of transfusion of 15 to 75 Packed Red Blood Cells (PRBC) units~* Anticipated to be transfused with at least 8 units of PRBCs annually during the study~* Women of child-bearing potential using effective methods of contraception during dosing of study treatment~Exclusion Criteria:~* More than 6 months of cumulative ICT (such as daily deferasirox (Exjade®) or deferiprone or 5×/week deferoxamine)~* More than 3 years since patient began receiving regular transfusions (2 units per 8 weeks or 4 units received in a 3 month period)~* Significant proteinuria~* History of hospitalization for congestive heart failure; other heart conditions as specified in the protocol~* Systemic diseases which would prevent study treatment~* Hepatitis B; Hepatitis C; HIV~* Liver cirrhosis~* Pregnant, or breast-feeding patients, or patients of child-bearing potential not employing an effective method of birth control~* History of drug or alcohol abuse within the 12 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): 10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
- Placebo (Type: PLACEBO_COMPARATOR): 10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.

Based on this trial design, predict the completion outcome and termination type (if applicable).